lumocaserin   Click here for help

GtoPdb Ligand ID: 14747

Synonyms: compound (+)-16a [PMID: 25633969]
Compound class: Synthetic organic
Comment: Lumocaserin is the INN for a serotonin 5-HT2C receptor agonist, with anti-epileptic potential. The structure provided in the INN record is identical to that for compound (+)-16a in [2], and additional 2-phenylcyclopropylmethylamine-based 5-HT2C agonists similar to lumocaserin are described in [3]. Analysis of available patent and peer-reviewed information around compounds with this core structural scaffold strongly suggests that lumocaserin is the INN for Bright Minds Biosciences' clinical candidate BMB-101, which is in development as an anti-epileptic agent. BMB-101 exhibits bias for Gq-mediated signaling. It does not induce β-arrestin recruitment and therefore does not cause 5-HT2C receptor desensitization.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 35.25
Molecular weight 223.29
XLogP 1.44
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCOC1=CC=C(C=C1[C@H]2C[C@@H]2CN)F
Isomeric SMILES CCCOC1=C(C=C(C=C1)F)[C@H]2C[C@@H]2CN
InChI InChI=1S/C13H18FNO/c1-2-5-16-13-4-3-10(14)7-12(13)11-6-9(11)8-15/h3-4,7,9,11H,2,5-6,8,15H2,1H3/t9-,11+/m1/s1
InChI Key PHNQBSADACIRLN-KOLCDFICSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
BMB-101 was progressed as a clinical candidate, primarily to evaluate it as a potential therapy for developmental and epileptic encephalopathies (DEEs) and drug-resistant absence seizures [1]. The FDA placed a partial hold on trial NCT06401538 in October 2026, due to issues around toxicity (in mice) and the lack of pharmacokinetic and juvenile toxicity data to support testing in paediatric patients.
A clinical trial has been designed to test BMB-101's efficacy to reduce appetite and weight gain in patients with Prader-Willi syndrome.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05397041 A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers Phase 1 Interventional Bright Minds Biosciences Pty Ltd
NCT06401538 BMB-101 in Absence Epilepsy and DEE Phase 2 Interventional Bright Minds Biosciences Pty Ltd
NCT07266324 A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. Phase 2 Interventional Bright Minds Biosciences Pty Ltd